Welcome to our dedicated page for Translational Development Acquisition SEC filings (Ticker: TDACW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Translational Development Acquisition Corp. (TDACW) files reports with the U.S. Securities and Exchange Commission as a blank check or special purpose acquisition company with securities registered under Section 12(b) of the Exchange Act. Its filings provide detailed information about its units, Class A ordinary shares and redeemable warrants, including the TDACW warrants, and describe how these securities are structured within its SPAC framework.
In its Form 8-K reports, the company discloses material events such as the creation of direct financial obligations and the entry into financing arrangements with its sponsor. One 8-K filing explains that on August 8, 2025, TDAC Partners LLC agreed to loan up to $2,000,000 to the company for working capital, documented in a non-interest-bearing promissory note. The note is repayable on the earlier of the deadline to complete a Business Combination or the effective date of a Business Combination, and is forgiven if no Business Combination occurs, except to the extent funds are available outside the trust account established in connection with the initial public offering.
SEC filings for Translational Development Acquisition Corp. also confirm that its units trade under TDACU, its Class A ordinary shares under TDAC and its redeemable warrants under TDACW on The Nasdaq Stock Market LLC. The filings specify that each unit consists of one Class A ordinary share and one-half of one redeemable warrant, and that each whole warrant is exercisable for one Class A ordinary share at an exercise price of $11.50.
On this filings page, users can review the company’s 8-K and other reports to understand how Translational Development Acquisition Corp. structures its capital, manages sponsor financing and defines its obligations in relation to its stated objective of completing a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar Business Combination.
Translational Development Acquisition Corp. reports its 2025 results as a blank check company focused on completing an initial business combination. It completed an IPO of 17,250,000 units at $10.00 each, plus 7,075,000 private placement warrants at $1.00, placing $174,225,000 into a trust at $10.10 per public share.
At December 31, 2025, investments in the trust totaled $181,657,311 and the company recorded net income of $6,362,427, driven by $7,306,965 of dividends on trust investments and $944,538 of operating costs. Cash outside the trust was $29,787 with a working capital deficit of $504,608.
The company has until June 24, 2026 to complete a business combination or redeem public shares and liquidate. Management discloses substantial doubt about its ability to continue as a going concern absent a timely deal or further sponsor support, while highlighting shareholder redemption protections and the sponsor’s limited indemnity for certain creditor claims.
Translational Development Acquisition Corp. disclosed that its sponsor agreed to loan the Company up to $2,000,000 for working capital. The loan is evidenced by a promissory note that is non-interest bearing and is repayable on the earlier of (i) the date by which the Company must complete a qualifying business combination under its Amended and Restated Memorandum of Association and (ii) the effective date of a business combination (the Maturity Date). The note’s issuance was made pursuant to an exemption under Section 4(a)(2) of the Securities Act of 1933. The filing includes Exhibits, including the promissory note (Exhibit 10.1) signed by Michael B. Hoffman as CEO.